Literature DB >> 837647

Individualization of phenytoin dosage regimens.

T M Ludden, J P Allen, W A Valutsky, A V Vicuna, J M Nappi, S F Hoffman, J E Wallace, D Lalka, J L McNay.   

Abstract

Two methods for arriving at optimum, individual phenytoin dosage regimens have been evaluated in 12 patients. (1) Individual Michaelis-Menten pharmacokinetic parameters for phenytoin were estimated from two reliable steady-state phenytoin serum concentrations resulting from different daily doses: The observed steady-state phenytoin serum levels obtained after 3 to 8 wk of compliance with dosage regimens calculated from the individual pharmacokinetic parameters agreed well with predicted levels (r = 0.824, p less than 0.02). The average deviation between observed and predicted levels was 0.04 mug/ml (range, +/- 3.2 mug/ml). (2) A previously published nomogram for making adjustments in phenytoin dosage regimens: The serum phenytoin concentration actually expected from the dose indicated by the nomogram was calculated using individual pharmacokinetic parameters. The daily dose for one patient would have exceeded his estimated maximal rate of metabolism. The correlation between calculated and predicted phenytoin serum levels in the other 11 patients was weak but significant (r= 0.360, p less than 0.05). The average deviation was --3 mug/ml (range, 3.9 to --11.3 mug/ml). It was concluded that the use of individual pharmacokinetic parameters is practical and is also superior to the nomogram.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837647     DOI: 10.1002/cpt1977213287

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics.

Authors:  Jovan Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jul-Sep       Impact factor: 2.441

Review 3.  Pharmacokinetic evaluation of hemodialysis in acute drug overdose.

Authors:  S Takki; J G Gambertoglio; D H Honda; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

Review 4.  Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application.

Authors:  S Vozeh; J L Steimer
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 5.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin.

Authors:  J C McElnay; G Uprichard; P S Collier
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

7.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

Authors:  T H Grasela; L B Sheiner; B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens; T Ishizaki; K Chiba
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

8.  Phenytoin dosage predictions in paediatric patients.

Authors:  G J Yuen; P T Latimer; L C Littlefield; R W Mackey
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

Review 9.  An updated comparison of drug dosing methods. Part I: Phenytoin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

10.  Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients.

Authors:  L A Bauer; R A Blouin
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.